The Centers for Disease Control and Prevention (CDC) has announced significant CDC immunization schedule updates that shift the approach to COVID-19 vaccinations for adults and change the administration of chickenpox vaccines for toddlers. The new guidelines move away from blanket recommendations for COVID-19 boosters in favor of a personalized, risk-based approach and recommend that children under three receive the varicella vaccine as a standalone shot.
These changes, which adopt recent recommendations from the Advisory Committee on Immunization Practices (ACIP), were approved by Jim O’Neill, the Deputy Secretary of Health and Human Services and Acting Director of the CDC. The updated schedules are slated to be officially published on the agency’s website by October 7, 2025.
For many patients and providers, the most notable shift is the transition to shared clinical decision-making for COVID-19. This model replaces the previous broad recommendations, emphasizing a dialogue between healthcare providers—including physicians, nurses and pharmacists—and their patients to determine if a vaccine is appropriate based on individual health profiles rather than age alone.
A Shift Toward Shared Clinical Decision-Making for COVID-19
Under the previous 2022 guidelines, the CDC issued blanket recommendations for perpetual COVID-19 boosters. Yet, the new framework acknowledges that the risk-benefit ratio varies significantly across different populations. For adults under age 65, the benefit of vaccination is now viewed as most favorable for those with specific risk factors for severe disease and lowest for those without such risks.
“Informed consent is back,” said Deputy Secretary O’Neill. “CDC’s 2022 blanket recommendation for perpetual COVID-19 boosters deterred health care providers from talking about the risks and benefits of vaccination for the individual patient or parent. That changes today.”
This policy pivot follows a sharp decline in booster uptake. While the primary vaccination series—launched via Operation Warp Speed—reached an estimated nearly 85% of the U.S. Adult population, only 23% of adults followed the most recent seasonal booster recommendation, according to the National Immunization Survey.
The CDC notes that as the virus became endemic and population-wide immunity grew, concerns regarding the safety and efficacy of repeated boosters increased. The U.S. Food and Drug Administration (FDA) continues to maintain marketing authorization for COVID-19 vaccines for those 65 and older, as well as individuals with one or more recognized risk factors for severe illness.
What “Individual-Based Decision-Making” Means for Patients
In practical terms, shared clinical decision-making means the decision to vaccinate is no longer a “one size fits all” directive. Instead, providers will evaluate specific patient characteristics, including:
- Underlying health conditions that increase the risk of severe COVID-19.
- The specific characteristics and evidence associated with the vaccine being offered.
- The patient’s personal health history and current immunity levels.
Despite the shift in how the vaccine is recommended, accessibility remains unchanged. Vaccination based on shared clinical decision-making is still covered by all major payment mechanisms, including Medicare, Medicaid, the Children’s Health Insurance Program (CHIP), and the Vaccines for Children Program, as well as insurance plans regulated by the Affordable Care Act.
Reducing Febrile Seizure Risks in Toddlers
The updates also introduce a critical change to the child and adolescent immunization schedule regarding varicella (chickenpox). The CDC now recommends that toddlers through age three receive the chickenpox vaccine as a standalone immunization rather than as part of the combined measles, mumps, rubella, and varicella (MMRV) vaccine.
This decision stems from data provided by the CDC Immunization Safety Office. Evidence presented to ACIP indicated that healthy toddlers between 12 and 23 months old face an increased risk of febrile seizures—convulsions triggered by fever—roughly seven to 10 days after receiving the combined MMRV shot.
According to the agency, the combination vaccine doubles the risk of these seizures compared to receiving the chickenpox vaccine separately, without providing any additional protection against varicella. By separating the shots, the CDC aims to protect children from these unintended side effects while maintaining the same level of immunity.
| Vaccine | Previous Approach | New Recommendation | Primary Driver for Change |
|---|---|---|---|
| COVID-19 | Blanket booster recommendations | Shared clinical decision-making | Risk-benefit variance & lower uptake |
| Varicella (Toddlers) | Combined (MMRV) vaccine | Standalone immunization | Reduction of febrile seizure risk |
The Path Forward for Public Health
The transition marks a broader effort to address vaccine safety signals and restore the role of the primary care provider in the vaccination process. Deputy Secretary O’Neill credited the expertise of the ACIP and the leadership of President Trump in prioritizing the protection of children from side effects during routine immunizations.
For parents and adults, the next step is to consult with their healthcare provider to review their specific risk factors and immunization history. These conversations will now be the primary driver for determining the timing and necessity of future doses.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or vaccination schedule.
The updated schedules will be fully integrated into CDC.gov by October 7, 2025, providing a finalized roadmap for clinicians and patients nationwide.
Do you have questions about how these changes affect your family’s health plan? Share your thoughts in the comments or share this article with your healthcare provider to start the conversation.
